According to Inc42 data covering the week of September 2‑8 2024 Indian startups closed 22 deals worth a total of $177 million. This marks a drop from the previous week’s $210 million and extends the funding decline into a second straight week. The largest rounds were Ultrahuman’s $25 million Series B led by Tiger Global and Steadview Capital and Comet’s $18 million Series A backed by Sequoia Capital India and Lightspeed Venture Partners. Other notable transactions included a $12 million round for a B2B SaaS player in the logistics space and a $9 million fintech credit platform raise.

The downturn reflects growing investor caution amid global interest rate volatility and a weakening rupee, which has raised the cost of capital for dollar‑denominated funds. Valuations are being reset, pushing founders to prioritize unit economics over growth at all costs, a shift that could weed out unsustainable business models but also strain hiring plans. Second‑order effects include a likely slowdown in talent migration to startups, increased pressure on early‑stage employees to accept lower equity packages, and a potential wave of consolidation as weaker players seek exits or bridge rounds to survive until market sentiment improves.

Winners are the companies that secured large rounds—Ultrahuman and Comet—and their lead investors, who gain footholds in high‑growth health‑tech and emerging logistics niches. Losers include early‑stage founders in sectors like edtech and enterprise software that saw deal flow thin out, as well as limited partners who are reallocating capital to safer public market assets. Global LPs appear to be pulling back from India‑focused funds, exacerbating the funding squeeze for nascent startups.

Watch for the Reserve Bank of India’s monetary policy stance in the coming weeks, as any further rate hikes could deepen the funding chill. Also monitor the government’s upcoming Startup India seed fund disbursements and any GST council rulings that affect SaaS pricing, which could either relieve or worsen pressure on tech margins. The health of the IPO pipeline—particularly any delayed listings from unicorns like Nykaa or Paytm—will signal whether exit opportunities are returning to revive investor appetite.